{Reference Type}: Case Reports
{Title}: Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient.
{Author}: Onuki T;Morita E;Sakamoto N;Nagai Y;Sata M;Hagiwara K;
{Journal}: Respirol Case Rep
{Volume}: 6
{Issue}: 6
{Year}: Aug 2018
暂无{DOI}: 10.1002/rcr2.334
{Abstract}: Pembrolizumab is an immune checkpoint inhibitor that induces side effects called "immune-related adverse events" (irAEs). Various types of organs are affected by irAEs, although reports of upper gastrointestinal disorders are rare. Here, we report a case of extensive inflammatory pathologies in the oesophagus, stomach, duodenum, and jejunum after the administration of pembrolizumab for non-small cell lung cancer.